SGMT
NASDAQ · Biotechnology
Sagimet Biosciences Inc-A
$5.55
+0.11 (+2.02%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 28.61M | 29.26M | 29.39M |
| Net Income | 3.39M | 4.16M | 4.24M |
| EPS | — | — | — |
| Profit Margin | 11.8% | 14.2% | 14.4% |
| Rev Growth | +24.7% | +14.4% | -5.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 26.81M | 31.18M | 23.95M |
| Total Equity | 64.77M | 65.54M | 66.31M |
| D/E Ratio | 0.41 | 0.48 | 0.36 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 5.59M | 5.60M | 5.84M |
| Free Cash Flow | 4.74M | 2.94M | 4.50M |